Yazar "Ilhan, Osman" için listeleme
-
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Lugtenburg, Pieternella; Avivi, Irit; Berenschot, Henriette; Ilhan, Osman; Marolleau, Jean Pierre; Nagler, Arnon; Pfreundschuh, Michael (Ferrata Storti Foundation, 2017)Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce ... -
Ibrutinib: From Molecule to Medicine
Ayyildiz, Orhan; Demirkan, Fatih; Goker, Hakan; Haznedaroglu, Ibrahim C.; Ilhan, Osman; Kaynar, Leyla G.; Vural, Filiz (Akad Doktorlar Yayinevi, 2014)Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition ... -
A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)
Kayikcioglu, Meral; Tokgozoglu, Lale; Yilmaz, Mehmet; Kaynar, Leylagul; Aktan, Melih; Durmus, Rana Berru; Ilhan, Osman (Elsevier Ireland Ltd, 2018)Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive ...
